921 related articles for article (PubMed ID: 31258539)
21. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
22. Thrombosis in myeloproliferative neoplasms.
Falanga A; Marchetti M
Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
[TBL] [Abstract][Full Text] [Related]
23. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
24. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
25. Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms.
He F; Laranjeira AB; Kong T; Lin S; Ashworth KJ; Liu A; Lasky NM; Fisher DA; Cox MJ; Fulbright MC; Antunes-Heck L; Yu L; Brakhane M; Gao B; Sykes SM; D'Alessandro A; Di Paola J; Oh ST
J Clin Invest; 2024 Feb; 134(3):. PubMed ID: 38060311
[TBL] [Abstract][Full Text] [Related]
26. [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].
He ZP; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):589-594. PubMed ID: 29665937
[TBL] [Abstract][Full Text] [Related]
27. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
Haybar H; Khodadi E; Shahjahani M; Saki N
Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
[TBL] [Abstract][Full Text] [Related]
29. Platelets and thrombosis in myeloproliferative diseases.
Harrison CN
Hematology Am Soc Hematol Educ Program; 2005; ():409-15. PubMed ID: 16304412
[TBL] [Abstract][Full Text] [Related]
30. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
Feng Y; Zhang Y; Shi J
Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
[TBL] [Abstract][Full Text] [Related]
31. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
32. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
Hasselbalch HC; Elvers M; Schafer AI
Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
[TBL] [Abstract][Full Text] [Related]
33. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
34. Procoagulant platelets: novel players in thromboinflammation.
Denorme F; Campbell RA
Am J Physiol Cell Physiol; 2022 Oct; 323(4):C951-C958. PubMed ID: 35993516
[TBL] [Abstract][Full Text] [Related]
35. Platelet-leukocyte interactions in thrombosis.
Cerletti C; Tamburrelli C; Izzi B; Gianfagna F; de Gaetano G
Thromb Res; 2012 Mar; 129(3):263-6. PubMed ID: 22075180
[TBL] [Abstract][Full Text] [Related]
36. JAK2 mutation-related disease and thrombosis.
Vannucchi AM; Guglielmelli P
Semin Thromb Hemost; 2013 Jul; 39(5):496-506. PubMed ID: 23633193
[TBL] [Abstract][Full Text] [Related]
37. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.
Moliterno AR; Ginzburg YZ; Hoffman R
Blood; 2021 Mar; 137(9):1145-1153. PubMed ID: 33237986
[TBL] [Abstract][Full Text] [Related]
38. Platelet Dysfunction and Thrombosis in JAK2
Matsuura S; Thompson CR; Belghasem ME; Bekendam RH; Piasecki A; Leiva O; Ray A; Italiano J; Yang M; Merill-Skoloff G; Chitalia VC; Flaumenhaft R; Ravid K
Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):e262-e272. PubMed ID: 32814440
[TBL] [Abstract][Full Text] [Related]
39. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
40. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
